These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 15516007)
1. Preliminary efficacy and safety of oral suspension SH, combination of five chinese medicinal herbs, in people living with HIV/AIDS ; the phase I/II study. Kusum M; Klinbuayaem V; Bunjob M; Sangkitporn S J Med Assoc Thai; 2004 Sep; 87(9):1065-70. PubMed ID: 15516007 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes. Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196 [TBL] [Abstract][Full Text] [Related]
3. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection. Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257 [TBL] [Abstract][Full Text] [Related]
4. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096 [TBL] [Abstract][Full Text] [Related]
5. Zidovudine and lamivudine: results of phase III studies. Staszewski S J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. Anekthananon T; Ratanasuwan W; Techasathit W; Sonjai A; Suwanagool S J Med Assoc Thai; 2004 Jul; 87(7):760-7. PubMed ID: 15521230 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients. Sangkitporn S; Shide L; Klinbuayaem V; Leenasirimakul P; Wirayutwatthana NA; Leechanachai P; Dettrairat S; Kunachiwa W; Thamlikitkul V Southeast Asian J Trop Med Public Health; 2005 May; 36(3):704-8. PubMed ID: 16124442 [TBL] [Abstract][Full Text] [Related]
8. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team. Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498 [TBL] [Abstract][Full Text] [Related]
9. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S; Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319 [TBL] [Abstract][Full Text] [Related]
10. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3. Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274 [TBL] [Abstract][Full Text] [Related]
11. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
12. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA; BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812 [TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B; Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750 [TBL] [Abstract][Full Text] [Related]
14. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS. AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371 [TBL] [Abstract][Full Text] [Related]
15. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023 [TBL] [Abstract][Full Text] [Related]
16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients. de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754 [TBL] [Abstract][Full Text] [Related]
19. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272 [TBL] [Abstract][Full Text] [Related]
20. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients]. Reynes J; Montes B; Delmas B; Vendrell JP; Janbon F; Segondy M Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]